Dublin, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The "Strategic Intelligence: Orphan Designated Drugs" report has been added to ResearchAndMarkets.com's offering.
This report consolidates the latest thinking and forecasts around how the healthcare, macroeconomic, technology, and regulatory trends will impact the orphan designated drugs in pharma space, as well as providing insights into the leading players and future challengers across the value chain, and providing insights into key drugs and markets from the Pharma Intelligence Center. Additionally, this report is designed to provide strategic planners, competitive intelligence professionals and key stakeholders in the pharmaceutical industry a clear view of the opportunities and risks over the foreseeable future.
Due to the unmet medical demands of many rare diseases around the world, the number of orphan designated drugs (ODD) by regulatory agencies such as the FDA and EMA has increased in recent years. This has arisen from international recognition of the significant number of people that rare diseases affect daily, paired with limited therapeutic options and low patient populations.
As a result, a wide variety of pharmaceutical companies are expanding their orphan drug portfolio through co-development partnerships and collaborations, innovative means of personalized and precision therapy, as well as receiving financial and legal support from regulatory bodies to meet this unmet medical need.
Report Scope
- A dedicated report examining the pivotal healthcare, technological, macroeconomic, and regulatory trends shaping the orphan designated drugs field in pharma landscape.
- This report also provides an in-depth analysis of how these trends are poised to either accelerate progress or create obstacles for the growth of the orphan designated drugs market.
- Understand the key trends accelerating or hindering the orphan designated drugs in pharma space.
Company Coverage Includes:
- AbbVie
- Pfizer
- Roche
- AstraZeneca
- Takeda
- Sanofi
- Catalent
- Merck and Co,
- Argenx
- CSL
- BeiGene
- Ipsen
- Regeneron
- Abzena
- Grifols
- Biogen
Key Topics Covered:
- Executive Summary
- Players
- Thematic Briefing
- Trends
- Healthcare trends
- Technology trends
- Macroeconomic trends
- Regulatory trends
- Industry Analysis
- Market size and growth forecasts
- Case studies
- Vyxeos Combination for IV Injection Receives Orphan Drug Designation for the Treatment of High-Risk AML in Japan
- Panavance Therapeutics Awarded ODD for its Pancreatic Cancer Treatment
- PhamAust Limited Reveals Encouraging Results for Monepantel
- Can-Fite Biopharma's Namodenoson Demonstrating Anti-cancer and Protective Effects in the Liver
- Signals
- M&A trends
- Strategic partnerships
- Funding
- Social media trends
- Value Chain
- Drug discovery and development
- Clinical trials
- Manufacturing
- Patient access
- Companies
- Public companies
- Private companies
- Sector Scorecards
- Clinical trials scorecard
- Who's who
- Thematic screen
- Valuation screen
- Risk screen
For more information about this report visit https://www.researchandmarkets.com/r/vnxu9r
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
